Meteospasmyl (Alverine Citrate, Simeticone)

Alverine citrate acts as a direct smooth‑muscle relaxant. It inhibits calcium influx into gastrointestinal smooth‑muscle cells, reducing involuntary contractions and spasm. This relaxation eases cramping and pain, while the accompanying simethicone lowers surface tension of gas bubbles to aid their elimination.

The appropriate dose of Meteospasmyl is determined by the prescribing healthcare professional based on the individual’s condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for Meteospasmyl in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To order Meteospasmyl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Meteospasmyl combines an antispasmodic (alverine citrate) with an antiflatulent (simethicone), offering both muscle‑relaxing and gas‑eliminating actions. Compared with single‑agent antispasmodics such as hyoscine butylbromide, Meteospasmyl may provide broader symptom relief for patients who also experience significant flatulence.

Meteospasmyl should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Meteospasmyl is taken orally, usually with a glass of water. The exact timing (e.g., before meals, after meals) and frequency are determined by the prescribing clinician. Swallow the tablet or capsule whole; do not crush or chew unless directed.

Serious adverse reactions, although rare, include allergic manifestations such as rash, urticaria, facial or lip swelling, and difficulty breathing (angioedema). If any of these signs appear, discontinue the medication immediately and seek medical attention.

Meteospasmyl should be avoided in individuals with known hypersensitivity to alverine citrate, simethicone, or any excipients in the formulation. It is also contraindicated in patients with complete gastrointestinal obstruction or severe hepatic/renal impairment unless a physician advises otherwise.